290 related articles for article (PubMed ID: 27026610)
1. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.
Cheng F; Zhao J; Fooksa M; Zhao Z
J Am Med Inform Assoc; 2016 Jul; 23(4):681-91. PubMed ID: 27026610
[TBL] [Abstract][Full Text] [Related]
2. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
Zhao J; Cheng F; Wang Y; Arteaga CL; Zhao Z
Mol Cell Proteomics; 2016 Feb; 15(2):642-56. PubMed ID: 26657081
[TBL] [Abstract][Full Text] [Related]
3. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
4. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
Zhao Y; Liu Y; Bai H
Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
[TBL] [Abstract][Full Text] [Related]
5. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
Cheng F; Hong H; Yang S; Wei Y
Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
[TBL] [Abstract][Full Text] [Related]
6. Integration of genetic variants and gene network for drug repurposing in colorectal cancer.
Irham LM; Wong HS; Chou WH; Adikusuma W; Mugiyanto E; Huang WC; Chang WC
Pharmacol Res; 2020 Nov; 161():105203. PubMed ID: 32950641
[TBL] [Abstract][Full Text] [Related]
7. Systems biology based drug repositioning for development of cancer therapy.
Turanli B; Altay O; Borén J; Turkez H; Nielsen J; Uhlen M; Arga KY; Mardinoglu A
Semin Cancer Biol; 2021 Jan; 68():47-58. PubMed ID: 31568815
[TBL] [Abstract][Full Text] [Related]
8. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
9. Drug Repurposing for Cancer Therapy in the Era of Precision Medicine.
K W To K; Cho WCS
Curr Mol Pharmacol; 2022; 15(7):895-903. PubMed ID: 35156588
[TBL] [Abstract][Full Text] [Related]
10. Drug repositioning based on gene expression data for human HER2-positive breast cancer.
Khanjani F; Jafari L; Azadiyan S; Roozbehi S; Moradian C; Zahiri J; Hasannia S; Sajedi RH
Arch Biochem Biophys; 2021 Nov; 712():109043. PubMed ID: 34597657
[TBL] [Abstract][Full Text] [Related]
11. Identification of important genes and drug repurposing based on clinical-centered analysis across human cancers.
Li Y; Dong YP; Qian YW; Yu LX; Wen W; Cui XL; Wang HY
Acta Pharmacol Sin; 2021 Feb; 42(2):282-289. PubMed ID: 32555508
[TBL] [Abstract][Full Text] [Related]
12. MD-Miner: a network-based approach for personalized drug repositioning.
Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
[TBL] [Abstract][Full Text] [Related]
13. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
14. A systematic analysis of FDA-approved anticancer drugs.
Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
[TBL] [Abstract][Full Text] [Related]
15. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
16. Drug repositioning by merging active subnetworks validated in cancer and COVID-19.
Lucchetta M; Pellegrini M
Sci Rep; 2021 Oct; 11(1):19839. PubMed ID: 34615934
[TBL] [Abstract][Full Text] [Related]
17. Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
Li X; Shong K; Kim W; Yuan M; Yang H; Sato Y; Kume H; Ogawa S; Turkez H; Shoaie S; Boren J; Nielsen J; Uhlen M; Zhang C; Mardinoglu A
EBioMedicine; 2022 Apr; 78():103963. PubMed ID: 35339898
[TBL] [Abstract][Full Text] [Related]
18. Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature.
Chang Y; Park H; Yang HJ; Lee S; Lee KY; Kim TS; Jung J; Shin JM
Sci Rep; 2018 Jun; 8(1):8857. PubMed ID: 29891981
[TBL] [Abstract][Full Text] [Related]
19. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.
Fang J; Cai C; Wang Q; Lin P; Zhao Z; Cheng F
CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):177-187. PubMed ID: 28294568
[TBL] [Abstract][Full Text] [Related]
20. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
